LIFEHOUSE: Description of the Tent Bucket -Immune Support

Immune Response Clinical Trial

— LIFEHOUSE  

Official title:

LIFEHOUSE: a Lifestyle Intervention and Functional Evaluation- a Health OUtcome SurvEy; Description of the Tent Bucket -Immune Support

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04734288
• Other study ID #: 2020-002
• Status: Completed
• Phase: N/A
• Start date: January 22, 2021
• Est. completion date: December 31, 2022

Study information

• Verified date: April 2022
• Source: Metagenics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This immune support program will be an extension to the existing LIFEHOUSE program. Essential employees in Gig Harbor, WA; Colonial Heights, VA; Lenexa, KS, and Santa Fe Springs, CA, will be offered complimentary supplementation with commercially available nutritional supplements supportive of immune health for several months. The outcome will be measured via blood parameters and questionnaire responses.

Description:

This program, as a component of the LIFEHOUSE program, will consist of data collection during a period of supplementation with commercially available nutritional supplements supportive of immune health. Employees, in Gig Harbor, WA; Colonial Heights, VA; Lenexa, KS, and Santa Fe Springs, CA, will be offered the opportunity to participate. The nutritional and inflammatory status will be captured via fingerstick biomarkers. Participants will receive in-home testing kits including instructions regarding the applicable fingerstick blood collections. Fingerstick testing will include 25-Hydroxy Vitamin D3 (25-OH D3) and high sensitivity c-reactive protein (hs-CRP) measurements at baseline, 1, and 2 (phase 1), or at baseline 1,2, 3, and 6 months intervals (phase 2). Participants will also be asked to complete applicable questionnaires (QNs) electronically monthly using standard software programs for questionnaire completion. This will include the Medical Outcome Study (MOS) Short Form (SF) -36 (baseline and monthly) and Health Status QNs including questions on compliance, wellbeing, lifestyle (exercise, shifts worked, medications and supplements, and diet) (baseline and monthly).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 7
• Est. completion date: December 31, 2022
• Est. primary completion date: July 31, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 69 Years

Eligibility

Inclusion Criteria:

• Male or Female
• Ages 18-69, inclusive
• Metagenics' employees in Gig Harbor, WA; Colonial Heights, VA; Lenexa, KS, and Santa Fe Springs, CA
• General good health
• Willing to give written informed consent to participate in the study

Exclusion Criteria:

• An allergy to any ingredient in Vit.D3 5000 and/or Immune Active
• A serious, unstable illness including cardiac, hepatic, renal, gastrointestinal, respiratory, endocrinologic, neurologic, psychiatric, immunologic/rheumatological, or oncological/hematologic disease.
• Hyperparathyroidism
• Granulomatous disorders including as sarcoidosis, tuberculosis, leprosy, berylliosis, histoplasmosis, and coccidioidomycosis
• Chronic renal insufficiency
• Nephrolithiasis
• Prior cancer diagnosis
• Known infection with human immunodeficiency virus (HIV), tuberculosis (TB), or Hepatitis B or C.
• Established psychiatric disease including moderate to severe depression, thought disorders and bipolar disorder
• Planned use of nutritional supplements (exclusive of multiple vitamin/mineral supplements and medical foods) containing in total more than 1,000 IU Vitamin D3 and/or 10 mg Zinc
• Use of pharmaceutical nitrates for any indication
• Use of drugs of abuse and recreational drugs/substances (such as but not limited to opioids, cocaine, phencyclidine (PCP), and methamphetamine)
• History of marijuana or cannabinoid abuse within 12 months prior to screening and for the duration of the study.
• History of alcohol abuse or a diagnosis of alcoholism within 12 months prior to screening and for the duration of the study.
• Pregnant or breastfeeding women
• Inability to comply with study and/or follow-up visits.
• Any concurrent condition (including clinically significant abnormalities in medical history, physical examination or laboratory evaluations) which, in the opinion of the Principal Investigator (PI), would preclude safe participation in this study or interfere with compliance.
• Any sound medical, psychiatric, and/or social reason which, in the opinion of the PI, would preclude safe participation in this study or interfere with compliance.

Related Conditions & MeSH terms

• Immune Response

Intervention

Dietary Supplement:
• Vit.D3 5000 IU, Immune Active
The subjects will receive monthly (for either 3 or 6 months): Vit.D3 5000 and Immune Active. The first phase includes 3 months of treatment and the second phase includes 6 months of treatment. An in-home Vit.D/ hs-CRP test kit and asked to self-administer a blood collection via fingerstick and return the kits for analysis within a few days. Two online questionnaires each month and asked to fill them out within a few days. It will either be the Medical Outcomes Study (MOS) Short Form (SF)-36 and the Health Status Baseline or Health Status Follow-up Questionnaire.

Locations

Country	Name	City	State
United States	Personalized Lifestyle Medicine Center	Gig Harbor	Washington

Sponsors (2)

Lead Sponsor	Collaborator
Metagenics, Inc.	MetaProteomics LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The benefit of nutritional supplements (Vit.D3 5000, Immune Active) on the improvement of health.	The primary objective is to demonstrate the benefit of specific nutritional supplements, Vit.D3 5000 and Immune Active, as measured by demonstrable improvements in health, specifically a marker of nutritional status (25-hydroxy Vitamin D3 (25-OH D3)) and a marker of immune balance (high sensitivity c-reactive protein (hs-CRP) in a real-world setting.	12 weeks (Phase 1) or up to 6 months (Phase 2)
Secondary	The benefit of nutritional supplements (Vit.D3 5000, Immune Active) on the improvement of quality of life.	The first secondary objective is to demonstrate the benefit of specific nutritional supplements, Vit.D3 5000 and Immune Active, as measured by demonstrable improvements in health, specifically upon quality of life as measured by Rand Medical Outcome Study 36-Item Short Form Survey (MOS SF-36).	12 weeks (Phase 1) or up to 6 months (Phase 2)
Secondary	The benefit of nutritional supplements (Vit.D3 5000, Immune Active) on the improvement of the absence of infections.	The second secondary objective is to demonstrate the benefit of specific nutritional supplements, Vit.D3 5000 and Immune Active, as measured by demonstrable improvements in health, specifically experience-defined events (tally of well days during assessed periods and absence of laboratory-confirmed SARS-CoV-2 and Influenza infections).	12 weeks (Phase 1) or up to 6 months (Phase 2)
Secondary	The benefit of nutritional supplements (Vit.D3 5000, Immune Active) on the improvement of weight and body composition.	The third secondary objective is to demonstrate the benefit of specific nutritional supplements, Vit.D3 5000 and Immune Active, as measured by demonstrable improvements in health, specifically in weight and body composition.	12 weeks (Phase 1) or up to 6 months (Phase 2)